Opus Genetics, Inc. (NASDAQ:IRD) Financings

Opus Genetics, Inc.

Financings

RaiseDate
Private placement of series B Non-Voting Convertible Preferred Stock
Announced: US$25M · US$3.39 a share
Buyers: Adage Capital Management; Trails Edge Capital Partners; Marshall Wace
Use of proceeds: Advance gene therapy clinical programs, working capital and general corporate purposes
Feb 13, 2026
Registered direct offering of equity securities
Closed: US$23M raised · US$2.09 a share
Buyers: Perceptive Advisors (led the financing); Balyasny Asset Management (led the financing); Nantahala Capital (participated)
Use of proceeds: Advance LCA5 and BEST-1 gene therapy clinical programs, working capital and general corporate purposes
Nov 12, 2025
Public offering of shares of common stock, or common stock equivalents, and warrants
Closed: US$20M raised · US$0.95 a share · Warrants at US$0.95 for 60 months · Craig-Hallum
Dealers: Craig-Hallum (lead)
Buyers: Perceptive Advisors; Nantahala Capital
Use of proceeds: Extending cash runway and funding key upcoming milestones for the gene therapy portfolio
Mar 31, 2025
Private placement of shares of common stock and warrants
Closed: US$1.5M raised · US$1.275 a share · Warrants at US$1.15 for 60 months
Buyers: George Magrath; Cam Gallagher
Insiders: CEO George Magrath and board chairman Cam Gallagher participated
Use of proceeds: Clinical development of OPGx-LCA5 and OPGx-BEST1 gene therapy programs, general corporate purposes and working capital
Mar 31, 2025

Read by 6ix AI from the company's releases